Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Neutral
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.8.9388.8290
Address
Suite 401 35 Lime Street Sydney, New South Wales (NSW) 2000
Description
PainChek Ltd. engages in the development and commercialization of mobile medical device applications. The company was founded on August 27, 2010 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.02 - 0.06
Trade Value (12mth)
AU$10,810.00
1 week
-5.41%
1 month
-23.91%
YTD
25%
1 year
26.95%
All time high
0.43
EPS 3 yr Growth
3.70%
EBITDA Margin
-356.30%
Operating Cashflow
-$7m
Free Cash Flow Return
-727.90%
ROIC
-848.40%
Interest Coverage
N/A
Quick Ratio
1.40
Shares on Issue (Fully Dilluted)
1649m
HALO Sector
Technology
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
06 June 25 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
05 June 25 |
PainChek has productive final FDA De Novo clearance meeting
×
PainChek has productive final FDA De Novo clearance meeting |
27 May 25 |
PainChek partners with Eldermark to expand US market reach
×
PainChek partners with Eldermark to expand US market reach |
20 May 25 |
PainChek appoints head of Business Development for US market
×
PainChek appoints head of Business Development for US market |
19 May 25 |
Notification of cessation of securities - PCK
×
Notification of cessation of securities - PCK |
19 May 25 |
Notification regarding unquoted securities - PCK
×
Notification regarding unquoted securities - PCK |
01 May 25 |
Quarterly Investor Presentation April 2025
×
Quarterly Investor Presentation April 2025 |
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 April 25 |
Quarterly update and Appendix 4C webinar
×
Quarterly update and Appendix 4C webinar |
16 April 25 |
R&D Tax Refund, FDA Review of Adult App & Infant App Launch
×
R&D Tax Refund, FDA Review of Adult App & Infant App Launch |
27 March 25 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
27 March 25 |
Notification regarding unquoted securities - PCK
×
Notification regarding unquoted securities - PCK |
27 March 25 |
Notification regarding unquoted securities - PCK
×
Notification regarding unquoted securities - PCK |
17 March 25 |
PainChek to present at NWR Virtual Healthcare Conference
×
PainChek to present at NWR Virtual Healthcare Conference |
17 March 25 |
Update to previous announcement
×
Update to previous announcement |
06 March 25 |
Application for quotation of securities - PCK
×
Application for quotation of securities - PCK |
06 March 25 |
Notification regarding unquoted securities - PCK
×
Notification regarding unquoted securities - PCK |
05 March 25 |
Notification regarding unquoted securities - PCK
×
Notification regarding unquoted securities - PCK |
28 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
26 February 25 |
Results of Meeting
×
Results of Meeting |
31 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
30 January 25 |
Quarterly update and Appendix 4C webinar
×
Quarterly update and Appendix 4C webinar |
24 January 25 |
Notice of General Meeting/Proxy Form
×
Notice of General Meeting/Proxy Form |
24 December 24 |
Notification of cessation of securities - PCK
×
Notification of cessation of securities - PCK |
23 December 24 |
Change of Director's Interest Notice x5
×
Change of Director's Interest Notice x5 |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.